Walleye Trading’s Allogene Therapeutics ALLO Stock Holding History

Walleye Trading’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-16,200	Closed	-$80K	–	4671
2023 Q1	$80K	Buy	+16,200	New	+$104K	﹤0.01%	3936
2022 Q4	–	Sell	-3,900	Closed	-$42K	–	4924
2022 Q3	$42K	Buy	+3,900	New	+$53K	﹤0.01%	4284
2022 Q2	–	Sell	-3,900	Closed	-$36K	–	5061
2022 Q1	$36K	Buy	+3,900	New	+$40.6K	﹤0.01%	4602
2021 Q3	–	Sell	-5,900	Closed	-$154K	–	5147
2021 Q2	$154K	Sell	5,900 -1,900	-24%	-$54.2K	﹤0.01%	4120
2021 Q1	$275K	Buy	+7,800	New	+$263K	﹤0.01%	3328
2020 Q4	–	Sell	-6,500	Closed	-$245K	–	4550
2020 Q3	$245K	Sell	6,500 -1,800	-22%	-$67.9K	﹤0.01%	2849
2020 Q2	$355K	Buy	+8,300	New	+$300K	﹤0.01%	2569

Other funds holding ALLO

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Walleye Trading's ALLO Position: Q2 2022 in Review

Walleye Trading sold out of Allogene Therapeutics (ALLO) in Q2 2022, closing a stake of 8,371 shares — an estimated $76K sold.

Walleye Trading first reported a position in ALLO in Q2 2021 and held it in 2 quarters. The position peaked at $76K in Q1 2022. 161 funds tracked by Wall St. Rank hold ALLO as of Q2 2022.

Walleye Trading reported no remaining Allogene Therapeutics position as of Q2 2022 after selling out during the quarter.
Walleye Trading sold 8,371 Allogene Therapeutics shares in Q2 2022, an estimated $76K.
Walleye Trading first reported a position in Allogene Therapeutics in Q2 2021 and held it in 2 quarters.
Walleye Trading's Allogene Therapeutics position peaked at $76K in Q1 2022.
161 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2022.

Based on Walleye Trading's 13F filing for Q2 2022, filed 8 Aug 2022.